Head-to-head · WeighScore
Fella Health vs Zealthy
By GLP-1 ScorecardUpdated
Score comparison
Fella Health has the higher recorded score — 64/100 to 46.7/100.
Fella Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Fella Health is a medication weight loss program built specifically for men, offering compounded GLP-1 treatments (semaglutide and tirzepatide) plus free 1:1 health coaching, board-certified clinician care, and a 6-month money-back guarantee.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Fella Health | Zealthy |
|---|---|---|
| WeighScore | 64/100 | 46.7/100 |
| Grade | C | C |
| Site position | #273 | #538 |
| Semaglutide | $299/mo (compounded) | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | $449/mo (compounded) | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | 20 states | 34 states |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #273 · C
Strengths
- Specialized vertical — program designed for men, particularly 'bigger guys'
- Free 1:1 health coaching included with the membership
- 6-month money-back guarantee if the program doesn't work
- Flat monthly price stays the same as your dose escalates
- Both compounded semaglutide and tirzepatide available
What to consider
- Limited to men's health vertical — not available to women
- Available in only 20 published states (not nationwide)
- Exact GLP-1 monthly cost not published on the public site — only an 'under $10/day' starting figure
- Pricing transparency below industry standard for compounded GLP-1 telehealth
Site position #538 · C
FDAWarning letter issued to FitRX, LLC dba Zealthy in September 2025. See the FDA warning-letter database.
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
What to consider
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued FitRX, LLC dba Zealthy a warning letter in September 2025; the letter is public in FDA's warning-letter database
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.